Part

KinectAir Launches Commercial Operations in Pacific Northwest

Retrieved on: 
Friday, May 13, 2022 - 6:16pm

KinectAir , the operating system of the private aviation and Advanced Air Mobility markets, today announced it has begun commercial operations via its first trusted network partner, Direct2 Air, a Part 135 operator based out of Bend, OR.

Key Points: 
  • KinectAir , the operating system of the private aviation and Advanced Air Mobility markets, today announced it has begun commercial operations via its first trusted network partner, Direct2 Air, a Part 135 operator based out of Bend, OR.
  • Providing service across the Pacific Northwest, KinectAir now operates revenue-generating, on-demand private flights from Truckee, California to Vancouver, Washington and from Reno, Nevada to Seattle, Portland, and any of the countless regional airfields in between.
  • View the full release here: https://www.businesswire.com/news/home/20220512006138/en/
    KinectAir Launches Commercial Operations in Pacific Northwest Under Part 135 partnership, Direct2 Air becomes first KinectAir trusted network partner making accessible, on-demand, point-to-point air travel a reality through its software platform (Photo: Business Wire)
    At KinectAir we provide the software solution for Part 135 operators today to dramatically improve their operational efficiency and revenue.
  • Our launch brings to market the software foundation - the enabler - of the emerging Advanced Air Mobility market, said Jonathan Evans, CEO, KinectAir.

Leap Therapeutics Reports First Quarter 2022 Financial Results

Retrieved on: 
Friday, May 13, 2022 - 12:00pm

CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.

Key Points: 
  • CAMBRIDGE, Mass., May 13, 2022 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the first quarter endedMarch 31, 2022.
  • Net Loss was$10.4 millionfor the first quarter 2022, compared to$9.1 millionfor the same period in 2021.
  • Research and development expenses were $7.8 millionfor the first quarter 2022, compared to$6.8 millionfor the same period in 2021.
  • General and administrative expenses were$2.8 millionfor the first quarter 2022, compared to$2.7 millionfor the same period in 2021.

Chinook Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 12, 2022 - 9:00pm

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.

Key Points: 
  • SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022.
  • In March 2022, Chinook presented an overview of the phase 2 AFFINITY clinical trial at the 4th Annual Chronic Kidney Disease (CKD) Drug Development Summit.
  • In February 2022, Chinook delivered an encore trials-in-progress presentations on the phase 3 ALIGN and phase 2 AFFINITY clinical trials at the ISN World Congress of Nephrology 2022.
  • In March 2022, Chinook presented a detailed overview of the BION-1301 program at the 4th Annual CKD Drug Development Summit.

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

Retrieved on: 
Thursday, May 12, 2022 - 1:00pm

SOUTH SAN FRANCISCO, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced it has initiated a Phase 1/1b clinical study of NGM438 for the treatment of patients with advanced solid tumors. With the initiation of this trial, all three of NGM Bio’s wholly-owned myeloid checkpoint inhibition and reprogramming product candidates – NGM438, a LAIR1 antagonist antibody; NGM707, a dual ILT2/ILT4 antagonist antibody; and NGM831, an ILT3 antagonist antibody – are now in the clinic. ILT2, ILT4, ILT3 and LAIR1 are myeloid checkpoints that may play a central role in establishing an immune-suppressive state in the tumor microenvironment. NGM707, NGM831 and NGM438 are engineered to release distinct myeloid checkpoints and reprogram myeloid cells to reverse immune suppression and enhance immune response in tumors.

Key Points: 
  • NGM707, NGM831 and NGM438 are engineered to release distinct myeloid checkpoints and reprogram myeloid cells to reverse immune suppression and enhance immune response in tumors.
  • NGM438 is an antagonist antibody product candidate engineered to inhibit LAIR1 being developed by NGM Bio for the treatment of advanced solid tumors.
  • Visit https://www.ngmbio.com/discovery-engine/publications/ to view this poster and all of NGM Bios immuno-oncology research presented at the 2022 AACR Annual Meeting.
  • NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease.

EquitiesFirst and 14 Peaks' Nimsdai Purja Begin Epic Journey to Top of the World

Retrieved on: 
Thursday, May 12, 2022 - 12:00pm

HONG KONG, May 12, 2022 /PRNewswire/ -- EquitiesFirst, the global asset-based financing corporation, today announced a new partnership with 14 Peaks mountaineer Nimsdai Purja MBE ("Nims") as he ascends Everest in May 2022.

Key Points: 
  • When the opportunity arose to be part of Nims' 2022 Everest ascent, and his next extraordinary journey, it was an immediate yes from all of us at EquitiesFirst.
  • As seen on 14 Peaks, Nims' Everest journey is sure to be another thrilling, action-packed story with courage, perseverance and human endeavour at its heart.
  • Since founding, EquitiesFirst has successfully completed US$3 billion in capital raising for clients around the world.
  • Only 44 climbers have achieved the feat of consecutively ascending all 14 of the world's highest peaks.

Sandro Torrieri Announces Purchase of Convertible Debentures of Carbeeza Inc.

Retrieved on: 
Wednesday, May 11, 2022 - 11:07pm

CALGARY, Alberta, May 11, 2022 (GLOBE NEWSWIRE) -- Sandro Torrieri ("Torrieri") announces that he has acquired 10% convertible unsecured debentures (the "Debentures") of Carbeeza Inc. (the"Company") in the aggregate principal amount of $2,000,000 (the"Purchased Debentures") pursuant to a non-brokered private placement.

Key Points: 
  • CALGARY, Alberta, May 11, 2022 (GLOBE NEWSWIRE) -- Sandro Torrieri ("Torrieri") announces that he has acquired 10% convertible unsecured debentures (the "Debentures") of Carbeeza Inc. (the"Company") in the aggregate principal amount of $2,000,000 (the"Purchased Debentures") pursuant to a non-brokered private placement.
  • The principal amount outstanding under each Debenture is convertible into common shares in the capital of the Company ("Common Shares") at a conversion price of $0.40 per Common Share, at the option of Torrieri prior to May 9, 2024.
  • The Purchased Debentures are convertible into 5,000,000 Common Shares, representing approximately 7.3% of the issued and outstanding Common Shares after giving effect to such conversion (assuming conversion in full of the principal amount of the Purchased Debentures).
  • A copy of the Early Warning Report filed by Torrieri will be available under the Company's profile on SEDAR at www.sedar.com.

ABLE Equipment Rental, Inc. upsizes current Asset Based Loan (ABL) with M&T Bank

Retrieved on: 
Wednesday, May 11, 2022 - 2:05pm

DEER PARK, N.Y., May 11, 2022 /PRNewswire-PRWeb/ -- ABLE Equipment Rental, Inc. of NY (ABLE) a supplier of Construction Equipment Rentals, Sales, Service and Parts, announced an increase to its' existing Asset Based Loan with M&T Bank as Lead Arranger and Administrative Agent. The $175 million facility is now comprised of a $125 million revolving line of credit along with the original $15 million term loan facility. Additionally, the transaction continues to provide ABLE with a $35 million accordion feature for future growth. The increased credit facility will be used to grow the company's rental fleet, provide for general corporate working capital, and more importantly provide for growth capital as the company expands its geographic footprint beyond the northeast markets.

Key Points: 
  • DEER PARK, N.Y., May 11, 2022 /PRNewswire-PRWeb/ -- ABLE Equipment Rental , Inc. of NY (ABLE) a supplier of Construction Equipment Rentals, Sales, Service and Parts, announced an increase to its' existing Asset Based Loan with M&T Bank as Lead Arranger and Administrative Agent.
  • The $175 million facility is now comprised of a $125 million revolving line of credit along with the original $15 million term loan facility.
  • Additionally, the transaction continues to provide ABLE with a $35 million accordion feature for future growth.
  • For more information on ABLE Equipment Rental, visit ableequipment.com or send an email to info@ableequipment.com .

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

Retrieved on: 
Wednesday, May 11, 2022 - 2:00pm

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the Company or Anebulo), today announced financial results for the three months ended March 31, 2022 and recent updates.

Key Points: 
  • Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the Company or Anebulo), today announced financial results for the three months ended March 31, 2022 and recent updates.
  • Operating expenses in the third quarter of fiscal 2022 were $1.9 million compared with $0.6 million in the same period in fiscal 2021.
  • Net loss in the third quarter of fiscal 2022 was $1.9 million, or $(0.08) per share, compared with a net loss of $0.6 million, or $(0.68) per share, in the third quarter of fiscal 2021.
  • Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

BioLineRx Reports First Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, May 11, 2022 - 12:00pm

TEL AVIV, Israel, May 11, 2022 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the first quarter ended March 31, 2022 and provides a corporate update.

Key Points: 
  • Financial Results for the Quarter Ended March 31, 2022:
    Research and development expenses for the quarter ended March 31, 2022 were $4.4 million, an increase of $0.1 million, or 3.7%, compared to $4.3 million for the quarter ended March 31, 2021.
  • General and administrative expenses for the quarter ended March 31, 2022 were $1.0 million, similar to the comparable period in 2021.
  • Non-operating income amounted to $1.3 million for the quarter ended March 31, 2022, compared to non-operating expenses of $4.6 million for the quarter ended March 31, 2021.
  • Net financial expenses amounted to $0.1 million for the quarter ended March 31, 2022, compared to net nancial expenses of $0.2 million for the quarter ended March 31, 2021.

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 11, 2022 - 11:30am

BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the first quarter ended March 31, 2022.

Key Points: 
  • BiomX Inc. (NYSE American: PHGE) (BiomX or the Company), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results, and provided a business update for the first quarter ended March 31, 2022.
  • In January 2022, BiomX announced that the Company received a Therapeutics Development Award of up to $5 million from the Cystic Fibrosis Foundation.
  • Net loss for the first quarter of 2022 was $8.2 million, compared to $8.4 million for the same period in 2021.
  • BiomX management will host a conference call and webcast today at 8:00 am ET to report financial results and business updates for the first quarter ended March 31, 2022.